Key Facts and Data Points

  • MIP Implementation: Minimum Import Price imposed on Penicillin G, its salts, 6‑APA and amoxicillin.
  • Duration: One‑year ceiling, starting February 2026.
  • Exemptions: 100% export‑oriented units (EOUs), SEZ units, and imports under Advance Authorization (AA) provided the inputs are not sold in the domestic tariff area.
  • Import Dependence: China supplies ~70% of raw materials for India’s pharma sector, valued at $10‑12 billion.
  • Related Schemes: Production Linked Incentive (PLI) for APIs; earlier MIP on sulphadiazine (Nov 2025).

Background and Context

  • Pharmaceutical Landscape: India is the world’s largest generic drug exporter but remains heavily dependent on imported Active Pharmaceutical Ingredients (APIs).
  • China’s Dominance: Low‑cost Chinese APIs have created a price‑war, threatening the viability of domestic manufacturers.
  • Policy Rationale: MIP acts as a price floor to prevent dumping and protect strategic domestic capacity for essential antibiotics.

Significance for India / Governance / Policy

  • Strategic Autonomy: Ensures self‑reliance in critical health inputs, aligning with the Atmanirbhar Bharat vision.
  • Public Health Security: Secures uninterrupted supply of essential antibiotics like Penicillin G, crucial for both treatment and prophylaxis.
  • Industrial Policy: Complements the PLI scheme by providing a protective barrier while encouraging capacity expansion.
  • Trade Implications: Demonstrates a calibrated use of non‑tariff barriers (price floors) rather than outright tariffs, balancing WTO commitments.

Related Constitutional / Legal Provisions

  • Article 301 & 302 (Trade): Allows the state to impose restrictions on imports in the public interest.
  • Foreign Trade (Development and Regulation) Act, 1992: Empowers the government to regulate imports/exports, under which MIP is framed.
  • WTO Agreement on Safeguards: The MIP can be justified as a safeguard measure against sudden surges of low‑priced imports.

References